Next 10 |
home / stock / gild / gild articles
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.92% on an annualized basis producing an average annual return...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrade...
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks...
Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...
Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...
Gilead Sciences, Inc. (NASDAQ:GILD) stock is moving higher Friday on continued strength following the company’s Phase 3 HIV data. What To Kno...
Thursday, Gilead Sciences Inc (NASDAQ:GILD) shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial indicating its twice-ye...
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday. Shares of KB Home (NYSE:KBH) rose during Thursday's se...
Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020. Magrolimab is a mo...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...